Worked with CEO to successfully complete Series A and B raises. Developed clinical plan to PoC for novel molecule. Following successful raise, oversaw implementation and completion of clinical plan from initiation through read-out, working with CEO and board.

Chief Medical Officer: Oversaw conduct and completion of phase 1b AD study, Phase 1a single and multiple ascending dose studies to support novel development program in amyloidosis; meetngs with pharma and investors

Experience includes:Leadership of neuroscience clinical development in early and late phases (previously as head of early phase neuroscience clinical at Lilly, currently therapeutic area head and VP for clinical neuroscience at Merck, responsible for partnering with discovery and commercial to provide line of sight across the neuroscience portfolio and to oversee clinical development activities from phase 2 on). Management responsiblity for physician group that has ranged between 6 and 25 individuals over the yearsLead 4 successful NDA submissions (atmoxetine/Strattera for ADHD at Lilly, tafluprost/Zioptan for glaucoma, suvorexant/Belsomra for sleep and sugammadex/Bridion for reversal of neuromuscular blockade in anesthesia) as well the associated advisory committee preparation and presentations. Current projects include BACE inhibitor in phase 3 for Alzheimer's, as well as multiple phase 2 prjects in Alzheimer's, other dementias, schizophrenia, and anesthesia. Previous phase 2/3 programs in Parkinson's and migraine.Design, oversight and reporting of multiple clinical trials across a broad range of indications within psychiatry, neurology, pain, opthalmology and anesthesia.Review and assessment of partnering and licensing opportunities, and oversight of multiple partnerships as joint steering committee memberExternally facing activities including grant review for NIMH and NIDA, DSMB chair for NIMH medications development program, active member of Institue of Medicine neuroscience forum, elected member of ACNP.

research physician, medical director, executive medical directorLed clinical development for atomoxetine (Strattera) from phase 2 through NDA submission and approvalSubsequently led early clinical development for neuroscience (psychiatry/neurology/pain)